investors.viridiantherapeutics.comViridian Therapeutics, Inc. - Investors & Media
investors.viridiantherapeutics.com Profile
Investors.viridiantherapeutics.com is a subdomain of viridiantherapeutics.com, which was created on 2019-05-29,making it 5 years ago.
Discover investors.viridiantherapeutics.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
investors.viridiantherapeutics.com Information
| HomePage size: 137.164 KB |
| Page Load Time: 0.134654 Seconds |
| Website IP Address: 162.159.130.11 |
investors.viridiantherapeutics.com Similar Website
| Maryland Real Estate Investors Association - Maryland Real Estate Investors Association |
| Western Midstream - Investors - Investors |
| OMNOVA Solutions - Investors - Investors |
| Investors | Marathon Oil Corporation - Investors |
| Axalta Coating Systems - Investors - Investors Overview |
| Investors & Media | Ionis Pharmaceuticals, Inc. |
| Investors | Horizon Therapeutics plc |
| Investors | PTC Therapeutics, Inc. |
| Viridian Energy |
| Acorda Therapeutics Inc - Investors |
| Inovio Pharmaceuticals, Inc. - INVESTORS & MEDIA |
| Investors | Flexion Therapeutics, Inc. |
| Connected Investors | Connect With Real Estate Investors |
| Investors - Toromont Industries Ltd. - Investors |
| Mirati Therapeutics Inc. - Investor & Media Relations |
investors.viridiantherapeutics.com PopUrls
| Viridian Therapeutics, Inc. - Investors & Media https://investors.viridiantherapeutics.com/overview/default.aspx |
| News https://investors.viridiantherapeutics.com/news/ |
| Governance Documents https://investors.viridiantherapeutics.com/governance/governance-documents/ |
| Analyst Coverage https://investors.viridiantherapeutics.com/analyst-coverage/ |
| Filings - Annual Reports https://investors.viridiantherapeutics.com/filings/annual-reports/ |
| Committee Composition - Governance https://investors.viridiantherapeutics.com/governance/committee-composition/ |
| Filings - Quarterly Results https://investors.viridiantherapeutics.com/filings/quarterly-results/ |
| SEC Filings https://investors.viridiantherapeutics.com/filings/sec-filings/ |
| Resources - Stock Quote https://investors.viridiantherapeutics.com/resources/stock-quote/ |
| Viridian Therapeutics, Inc. - Viridian Therapeutics Reports Third ... https://investors.viridiantherapeutics.com/news/news-details/2023/Viridian-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corp |
| Viridian Therapeutics, Inc. - Viridian Therapeutics Highlights Recent ... https://investors.viridiantherapeutics.com/news/news-details/2024/Viridian-Therapeutics-Highlights-Recent-Progress-and-Reports-Fourth-Quarter-and-Full |
| Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 ... https://investors.viridiantherapeutics.com/news/news-details/2023/Viridian-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-an |
| Viridian Therapeutics, Inc. - Filings - Annual Reports https://investors.viridiantherapeutics.com/filings/annual-reports/default.aspx |
| Viridian Therapeutics, Inc. - Viridian Announces Positive Data from ... https://investors.viridiantherapeutics.com/news/news-details/2023/Viridian-Announces-Positive-Data-from-Ongoing-Phase-12-Trial-Evaluating-VRDN-001-in- |
| Viridian Therapeutics, Inc. - Viridian Therapeutics Reports First ... https://investors.viridiantherapeutics.com/news/news-details/2023/Viridian-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Corp |
investors.viridiantherapeutics.com Httpheader
| Date: Sun, 12 May 2024 16:05:49 GMT |
| Content-Type: text/html; charset=utf-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| CF-Ray: 882ba70828693119-LAX |
| CF-Cache-Status: REVALIDATED |
| Cache-Control: public, max-age=10, stale-if-error=86400, stale-while-revalidate=86400 |
| Strict-Transport-Security: max-age=31536000; includeSubDomains |
| Vary: Accept-Encoding |
| X-Content-Type-Options: nosniff |
| X-Frame-Options: SAMEORIGIN |
| X-XSS-Protection: 1; mode=block |
| Server: cloudflare |
investors.viridiantherapeutics.com Meta Info
| content="text/html; charset=utf-8" http-equiv="Content-type"/ |
| content="RevealTrans(Duration=0,Transition=0)" http-equiv="Page-Enter"/ |
| content="IE=edge,chrome=1" http-equiv="X-UA-Compatible"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
| content="default-src 'self' https: http: 'unsafe-inline' 'unsafe-eval' *.q4inc.com; script-src 'self' *.userway.org *.cookielaw.org *.bootstrapcdn.com *.datatables.net *.cloudfront.net *.pusherapp.com *.newrelic.com *.nr-data.net *.bugherd.com *.q4cdn.com *.q4web.com *.amazonaws.com *.highcharts.com *.googletagmanager.com *.googleadservices.com *.google-analytics.com *.google.com *.gstatic.com *.q4app.com *.pendo.io 'unsafe-inline' 'unsafe-eval' *.q4inc.com" http-equiv="Content-Security-Policy"/ |
| content="dufIxCzbIwx_0K-wnEfurdY-jbnpCTkjUZL1EFbUjnw" name="google-site-verification"/ |
investors.viridiantherapeutics.com Html To Plain Text
Viridian Therapeutics, Inc. - Investors & Media Overview News Events & Presentations Analyst Coverage Filings Quarterly Results Annual Reports SEC Filings Governance Governance Documents Our Team Committee Composition Resources Stock Quote Investor Email Alerts Investor & Media Contacts Please ensure Javascript is enabled for purposes of website accessibility Investors & Media Overview News Events & Presentations Analyst Coverage Filings Quarterly Results Annual Reports SEC Filings Governance Governance Documents Our Team Committee Composition Resources Stock Quote Investor Email Alerts Investor & Media Contacts Corporate Overview Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases. Latest News View All News Corporate Presentation Upcoming & Recent Events View All Events More Results Quick Links Viridian Therapeutics SEC Filings Events & Presentations Quarterly Results IR Contact Louisa Stone Manager, Investor Relations contact us by phone 617-272-4604 [email protected] Media Contact [email protected] Investor Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At Viridian Therapeutics, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Viridian Therapeutics, Inc. to send you the requested Investor Email Alert updates. * Required Email Address * Investor Alert Options Investor Alert Options * News Quarterly Reports Annual Reports SEC Filings End of Day Stock Quote Events & Presentations Unsubscribe Email Alert Sign Up Confirmation © 2023 Viridian Therapeutics, Inc. - All rights reserved Powered By Q4 Inc. 5.122.0.3 (opens in new window) Privacy Policy Cookie Policy Terms of Use Site...
investors.viridiantherapeutics.com Whois
Domain Name: VIRIDIANTHERAPEUTICS.COM Registry Domain ID: 2396306667_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2023-05-30T14:02:24Z Creation Date: 2019-05-29T14:54:19Z Registry Expiry Date: 2024-05-29T14:54:19Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS53.DOMAINCONTROL.COM Name Server: NS54.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T13:41:18Z <<<